Brookstone Capital Management
HUMA icon

Brookstone Capital Management’s Humacyte HUMA Stock Holding History

Brookstone Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.24K Buy
13,984
+730
+6% +$467 ﹤0.01% 1315
2026
Q2 		$10.3K Buy
13,254
+1,401
+12% +$1.3K ﹤0.01% 1308
2026
Q1 		$7.19K Sell
11,853
-2
-0% -$2 ﹤0.01% 1202
2025
Q4 		$11.4K Buy
11,855
+100
+0.9% +$142 ﹤0.01% 1161
2025
Q3 		$20.5K Hold
11,755
– – ﹤0.01% 1131
2025
Q2 		$24.6K Buy
11,755
+250
+2% +$480 ﹤0.01% 1056
2025
Q1 		$19.6K Buy
11,505
+400
+4% +$1.5K ﹤0.01% 1008
2024
Q4 		$56.1K Buy
+11,105
New +$54.9K ﹤0.01% 978

Other funds holding HUMA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Antipodes Partners
Antipodes Partners Royal Exchange, Australia $5.43B AUM 15.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Endowment Wealth Management
Endowment Wealth Management Appleton, Wisconsin $292M AUM 11.49% 1-Year Est. Return
Private Advisor Group
Private Advisor Group Morristown, New Jersey $29.9B AUM 19.22% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Brookstone Capital Management's HUMA Position: Q3 2026 in Review

Brookstone Capital Management increased its Humacyte (HUMA) stake by 5.5% in Q3 2026, buying an estimated $467 and bringing the position to 13,984 shares worth $7.24K. The position accounts for ﹤0.01% of the portfolio, ranked #1315.

Brookstone Capital Management first reported a position in HUMA in Q4 2024 and has held it in 8 quarters since. The position peaked at $56.1K in Q4 2024. 98 funds tracked by Wall St. Rank hold HUMA as of Q3 2026.

  • Brookstone Capital Management held 13,984 shares of Humacyte worth $7.24K as of Q3 2026.
  • Brookstone Capital Management bought 730 Humacyte shares in Q3 2026, an estimated $467.
  • Humacyte made up ﹤0.01% of Brookstone Capital Management's portfolio in Q3 2026, its #1315 holding.
  • Brookstone Capital Management first reported a position in Humacyte in Q4 2024 and has held it in 8 quarters since.
  • Brookstone Capital Management's Humacyte position peaked at $56.1K in Q4 2024.
  • 98 funds tracked by Wall St. Rank held Humacyte as of Q3 2026.

Based on Brookstone Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.